Precision oncology in cholangiocarcinoma integrates molecular taxonomy testing strategies and treatment sequencing.

Source: PubMed, NCBI / U.S. National Library of Medicine

Cholangiocarcinoma (CCA) is biologically heterogeneous, and timely molecular profiling is increasingly critical for treatment selection in unresectable, recurrent, or metastatic disease. Beyond guideline-style summaries, we provide an implementation-oriented framework that operationalizes testing and treatment sequencing across the disease course. We integrate molecular taxonomy with practical assay selection (tissue DNA/RNA and complementary ctDNA), specimen adequacy triage, reporting standards, and resistance-informed re-profiling at progression. We propose a stepwise decision algorithm and an end-to-end workflow (graphical abstract) aligned to real-world decision windows, including pragmatic turnaround-time (TAT) milestones and escalation triggers to mitigate common pre-analytic and analytic failure modes. We also address health-system variability and drug access considerations that influence feasibility, and we outline patient selection criteria, evidence thresholds, and cost-benefit considerations for repeat biopsy and serial ctDNA monitoring. Finally, we highlight patient-reported outcomes as complementary implementation endpoints relevant to regulatory and healthcare decision-making. This pragmatic framework aims to improve the consistency, speed, and clinical actionability of precision oncology in advanced CCA.